X4 Pharmaceuticals (XFOR) Operating Income Growth (1y) (2018 - 2025)
X4 Pharmaceuticals (XFOR) Operating Income Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 1,386.07% |
| 10 | X4 Pharmaceuticals | 165.58 Mn | -51.47 Mn | 2.20 Mn | 33.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 33.64% |
| Sep 30, 2025 | 20.26% |
| Jun 30, 2025 | -136.89% |
| Mar 31, 2025 | 74.68% |
| Dec 31, 2024 | -41.73% |
| Sep 30, 2024 | -26.77% |
| Jun 30, 2024 | 375.54% |
| Mar 31, 2024 | -27.25% |
| Dec 31, 2023 | 1.48% |
| Sep 30, 2023 | -35.03% |
| Jun 30, 2023 | -25.45% |
| Mar 31, 2023 | -37.78% |
| Dec 31, 2022 | 11.97% |
| Sep 30, 2022 | -5.41% |
| Jun 30, 2022 | -8.28% |
| Mar 31, 2022 | -18.58% |
| Dec 31, 2021 | -64.57% |
| Sep 30, 2021 | -12.60% |
| Jun 30, 2021 | -29.60% |
| Mar 31, 2021 | -69.51% |